Drug Development – Healthcare Economist

CBO: Impact of price control legislation on new drug development

2021-08-29Jason ShafrinLeave a comment

It stands to reason that policies that aim to reduce drug prices or squeeze life science companies profits are likely to decrease incentives to finance the research and development needed to bring a drug to market. Previous estimates claim that bringing a new drug to market may cost over $2 billion, and life science companies…

Does the government really need to provide financial support for COVID vaccine development?

2020-09-012020-09-01Jason ShafrinLeave a comment

Based on an a medRχiv working paper by Vu by et al. (2020), the answer from an analysis of other emerging infectious diseases (EIDs) is an overwhelming ‘yes’. The authors analyze hypothetical investment returns of a portfolio of 141 pre-clinical emerging infectious disease (EID) vaccine development programs across different emerging infections without a vaccine. These…